Deficient BIM Expression as a Mechanism of Intrinsic and Acquired Resistance to Targeted Therapies in EGFR-Mutant and ALK-Positive Lung Cancers

Abstract

This project has made very good progress. We have now unveiled an even larger role for defective apoptosis in the emergence of resistance. We have been very successful in our ability to generate cell lines derived from patient biopsies both before treatment and at the time of resistance. We are now using these patient-derived cell lines to assess BIM levels and apoptotic response to next-generation inhibitors.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2016
Accession Number
AD1030130

Entities

People

  • Jeffrey Engelman
  • Lecia Sequist

Organizations

  • Massachusetts General Hospital

Tags

DTIC Thesaurus Topics

  • Acquisition
  • Apoptosis
  • Biomedical Research
  • Cancer
  • Cell Line
  • Cell Physiological Processes
  • Cells
  • Chemistry
  • Clinical Trials
  • Genetics
  • Health Services
  • Inhibitors
  • Mathematical Models
  • Medical Personnel
  • Neoplasms
  • Oncology
  • Therapy

Fields of Study

  • Medicine

Readers

  • Facility/Structural Engineering.
  • Oncology
  • Prostate Cancer Biology.